GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.11 USD
+0.20 (0.49%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $41.12 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Price, Consensus and EPS Surprise
GSK 41.11 +0.20(0.49%)
Will GSK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
Why the Market Dipped But GSK (GSK) Gained Today
Illumina (ILMN) Expected to Beat Earnings Estimates: Should You Buy?
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
GSK Gears Up for Q1 Earnings: Here's What to Expect
Other News for GSK
June 7th Options Now Available For GSK
UK earnings, trading statements calendar - next 7 days
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
What's Going On With Pfizer Stock On Thursday?
GSK sues Pfizer, BioNTech over COVID-19 vaccines patents